ThermoGenesis (THMO) Stock Price, News & Analysis

Company Overview

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 4,517 shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

THMO Stock Analysis - Frequently Asked Questions

How were ThermoGenesis' earnings last quarter?

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) posted its earnings results on Friday, November, 12th. The company reported ($6.75) earnings per share for the quarter, missing analysts' consensus estimates of ($3.60) by $3.15. The business earned $3.16 million during the quarter, compared to analysts' expectations of $3.06 million.

When did ThermoGenesis' stock split?

ThermoGenesis's stock reverse split on the morning of Friday, December 23rd 2022.The 1-45 reverse split was announced on Friday, December 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ThermoGenesis?

Shares of THMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ThermoGenesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ThermoGenesis investors own include FuelCell Energy (FCEL), Teladoc Health (TDOC), Zoom Communications (ZM), Bionano Genomics (BNGO), Co-Diagnostics (CODX), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 9/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Laboratory apparatus & furniture
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:THMO
• CIK: 811212
• Web: www.thermogenesis.com
• Phone: (916) 858-5100
• Fax: 916-858-5199
• Employees: 40
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $9.61 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.99) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,953,000
• Free Float: 1,750,000
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: 1.18